Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics (Nasdaq: DMAC) will participate in the 2026 RBC Capital Markets Global Healthcare Conference in New York City. President and CEO Rick Pauls is scheduled for a fireside chat on Tuesday, May 19, 2026, from 4:05–4:30 PM ET, with additional one-on-one investor meetings available.
DiaMedica Therapeutics (NASDAQ: DMAC) reported first quarter 2026 results and clinical updates on May 6, 2026. The company had $51.3 million in cash and short-term investments as of March 31, 2026, and expects runway through 2027. ReMEDy2 AIS trial enrollment surpassed 70%, with an interim analysis planned in 4Q 2026. Multiple preeclampsia (PE) and fetal growth restriction (FGR) investigator-sponsored and Phase 2 programs are active, with several readouts and a UK CTA planned in 2Q 2026.
DiaMedica Therapeutics (Nasdaq: DMAC) will release first quarter 2026 financial results after market close on May 6, 2026, and host a business update conference call on May 7, 2026 at 8:00 AM ET.
Webcast access, dial‑in details, replay instructions through May 14, 2026, and a 12‑month on‑demand webcast availability are provided. DiaMedica focuses on treatments for preeclampsia, fetal growth restriction and acute ischemic stroke; lead candidate DM199 is a recombinant KLK1 therapeutic.
DiaMedica Therapeutics (Nasdaq: DMAC) reported full-year 2025 results and a business update. Key highlights include $59.9M cash and short-term investments, runway through 2H 2027, Health Canada clearance to start a Phase 2 DM199 trial in Canada, and ReMEDy2 AIS trial near 70% enrollment for interim analysis in 2H 2026.
R&D and operating cash use increased in 2025 as clinical programs expanded; management will host a webcast on March 31, 2026.
DiaMedica Therapeutics (Nasdaq: DMAC) will release full-year 2025 financial results after market close on March 30, 2026 and will host a business update and conference call on March 31, 2026 at 7:00 AM CDT.
Investors can join via webcast or dial-in; the webcast will be available for playback on the company's investor relations site for 12 months and a telephonic replay is available through April 7, 2026. DiaMedica is a clinical-stage biopharma developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke.
DiaMedica Therapeutics (Nasdaq: DMAC) received a No Objection Letter from Health Canada to start a Phase 2 study of DM199 for early-onset preeclampsia. The open-label, dose-ranging trial targets pregnancies at 24–32 weeks, will test three subcutaneous dose levels every three days until delivery, and is planned to start in 2026 with expansion into the United States and United Kingdom as additional regulatory clearances are obtained. The study will assess safety, tolerability and exploratory biomarkers including uterine artery pulsatility index, sFlt-1 and placental growth factor.
DiaMedica Therapeutics (Nasdaq: DMAC) will participate in three investor conferences in March 2026, presenting management updates and participating in fireside chats and a company presentation.
Management engagement dates: TD Cowen on March 2 at 11:50 a.m. ET; Barclays on March 10 at 10:00 a.m. ET; Leerink on March 11 at 3:00 p.m. ET. Investors may request 1×1 meetings via conference representatives.
DiaMedica (Nasdaq: DMAC) granted an aggregate of 50,000 stock options on January 15, 2026 as a material inducement to a newly hired non-executive employee whose employment began in December 2025. The options were approved by the Compensation Committee and issued under the Amended and Restated 2021 Employment Inducement Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $8.54 per share (equal to the closing price on January 15, 2026), vest 25% at the one-year anniversary and the remaining 75% in 12 quarterly installments beginning three months after the one-year anniversary, and carry a ten-year term.
DiaMedica Therapeutics (Nasdaq: DMAC) completed an in-person pre-IND meeting with the FDA for a planned study of DM199 in preeclampsia. The FDA requested one additional non-clinical 10-day modified embryo-fetal development and pre-/postnatal development study in rabbits; DiaMedica has begun preparations and expects results by Q2 2026. The company said meeting minutes provide regulatory clarity as it prepares an IND for early-onset preeclampsia.
Separately, an ongoing Phase 2 investigator-sponsored trial in South Africa has dosed >30 women with late-stage PE; interim data reportedly show statistically significant blood pressure reductions, dilation of intrauterine arteries, and no placental transfer of DM199.
DiaMedica Therapeutics (Nasdaq: DMAC) reported third quarter 2025 results and a business update on November 12, 2025. Key clinical updates include completion of cohort 10 and initiation of an up-to-12 participant expansion cohort in the Phase 2 IST for preeclampsia (completion of the expansion expected in 1H 2026), screening to begin soon for a Part 3 fetal growth restriction cohort, and an in-person pre-IND meeting with the FDA for U.S. PE plans. Enrollment in the ReMEDy2 Phase 2/3 AIS trial is nearing 50% of the 200-patient interim-analysis target, expected in 2H 2026. Financials: $55.3M cash and short-term investments as of September 30, 2025, with anticipated runway into 2H 2027. Net loss was $24.0M for the nine months ended September 30, 2025.